Propanc Biopharma has successfully raised $4 million in its Nasdaq debut. The company intends to use the funds to support upcoming cancer clinical trials. This news marks a significant milestone for the biopharmaceutical company as it continues to advance its innovative cancer treatments.

Read more at Investing.com: Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials